Pathogenics Inc.’s management team has particular expertise in biopharmaceutical development and licensing, and have been involved in the establishment and management of several small and medium size (SME) biopharmaceutical companies.
Frederic P. Zotos, Esq.
Frederic P. Zotos, Esq., is a Co-founder and Director of Pathogenics Inc., and he has served as its President and Chief Executive Officer since the Company was incorporated in 2005. He had previously served as managing member of the Company’s predecessor, Pathogenics LLC since its formation in 2002. Mr. Zotos brings to the Company his proven skills in patent licensing and business development, technology management and corporate finance.
Mr. Zotos has served on the board of directors for several companies including: Atlantic Technology Ventures Inc. (NASDAQ Smallcap: ATLC and OTC BB: ATLC.OB); Gemini Technologies Inc. (anti-sense gene therapy drugs); Optex Ophthalmologics Inc. (ophthalmic surgery devices); Channel Therapeutics Inc. (analgesic and anti-inflammatory therapeutic compounds); and Tera Comm Research Inc. (superconducting electronic fiber-optic transceivers).
Mr. Zotos is a registered patent attorney with the United States Patent and Trademark Office, and is also registered to practice law in Massachusetts and Connecticut. Mr. Zotos received a Bachelors degree in Mechanical Engineering from Northeastern University, a Masters Degree in Business Administration and a Juris Doctorate from Northeastern University, and successfully completed an M.S. in Electrical Engineering Prerequisite Program.